Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M, von der Maase, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/
https://www.ncbi.nlm.nih.gov/pubmed/15026795
http://dx.doi.org/10.1038/sj.bjc.6601709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/
https://www.ncbi.nlm.nih.gov/pubmed/15026795
http://dx.doi.org/10.1038/sj.bjc.6601709

Ejemplares similares